Vertex Pharmaceuticals (VRTX) Q3 2026 Earnings
Non-GAAP EPS excludes $502.0 million of acquisition-related costs (primarily compensation for cash-settled unvested Crinetics equity awards and transaction costs), $174.4 million of stock-based compensation, $20.9 million of intangible amortization and $5.4 million of acquired inventory step-up; GAAP diluted EPS was $2.56.
How Did VRTX Stock React to Q3 2026 Earnings?
Did VRTX Beat Earnings? Q3 2026 Results
Yes. Vertex Pharmaceuticals reported Q3 2026 earnings of $4.76 a share on Nov 2, 2026, beating the $4.75 consensus estimate by 0.2%. Revenue was $3.4B against a $3.4B estimate.
Vertex Pharmaceuticals posted a narrow but clean beat in the third quarter of 2026, with adjusted EPS of $4.76 edging past the $4.75 consensus and revenue of $3.44 billion topping estimates by 0.30% as the company's push <a href="https://247wallst.com/investing/2026/10/26/the-500-million-non-cf-factor-vertex-investors-cant-ignore-on-nov-2/">beyond cystic fibrosis</a> showed tangible momentum. Total revenue grew 11.8% year over year, driven by strong CF patient demand, accelerating ALYFTREK adoption, and early contributions from CASGEVY, JOURNAVX, and PALSONIFY, the acromegaly treatment that arrived via the September 1 closing of the Crinetics Pharmaceuticals acquisition. That deal weighed heavily on GAAP results, where roughly $502 million in acquisition-related costs pulled GAAP diluted EPS to $2.56 versus the adjusted $4.76, while non-GAAP net income held roughly flat at $1.21 billion. Looking ahead, management lifted full-year 2026 revenue guidance to $13.15 to $13.25 billion, with an FDA decision on povetacicept in IgA nephropathy due November 30 standing as the most immediate catalyst for Vertex's next leg of growth.
- Continued strong CF patient demand, including new ALYFTREK initiations
- Higher realized net prices in CF in the U.S.
- Increased CASGEVY infusions; CASGEVY revenue up 30% quarter over quarter
- JOURNAVX prescriptions of more than 750,000, up more than 40% quarter over quarter
- PALSONIFY contribution following the Crinetics acquisition close on September 1
- Favorable foreign exchange impact outside the U.S.
- About $502.0 million of Crinetics acquisition-related costs weighed on GAAP results
- Higher interest expense and lower interest income from acquisition financing
“Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition.”
Vertex Pharmaceuticals CEO, on the earnings call
What Is Vertex Pharmaceuticals's Outlook?
Vertex raised full-year 2026 total revenue guidance to $13.15–$13.25 billion from $13.1–$13.2 billion. The outlook assumes: - continued CF growth; - $500 million or more combined revenue from CASGEVY and JOURNAVX; - $40–$50 million of PALSONIFY revenue; - a roughly 150 basis point foreign-exchange benefit. Combined GAAP R&D, AIPR&D and SG&A expense guidance rose to $7.15–$7.2 billion from $6.3–$6.45 billion. This includes about $500 million of Crinetics compensation and transaction costs. Non-GAAP guidance rose to approximately $6.0 billion from $5.65–$5.75 billion. Non-GAAP effective tax rate guidance is unchanged at 19.5%–20.5%. Near-term milestones: - povetacicept IgAN PDUFA on November 30, 2026; - VX-670 DM1 interim data in 2H 2026; - inaxaplin AMPLITUDE interim analysis data in early 2027; - povetacicept gMG data in 1H 2027; - completion of atumelnant Phase 3 CAH enrollment in Q1 2027; - suzetrigine and VX-993 DPN results in mid-2027; - VX-017 pivotal development in 2027; - PALSONIFY European launches in 2H 2027.
VRTX YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $3.4B | $3.1B | +11.9% |
| Operating Income | $712.9M | $1.2B | −39.9% |
| Net Income | $653.6M | $1.1B | −39.6% |
VRTX Revenue by Segment
VRTX Revenue by Geography
When Does Vertex Pharmaceuticals Report Next?
Figures from SEC filings and company reports. Not investment advice.